ATE426167T1 - Auto-antikírper gegen annexin-proteine als marker fur lungenkrebs - Google Patents

Auto-antikírper gegen annexin-proteine als marker fur lungenkrebs

Info

Publication number
ATE426167T1
ATE426167T1 AT06075982T AT06075982T ATE426167T1 AT E426167 T1 ATE426167 T1 AT E426167T1 AT 06075982 T AT06075982 T AT 06075982T AT 06075982 T AT06075982 T AT 06075982T AT E426167 T1 ATE426167 T1 AT E426167T1
Authority
AT
Austria
Prior art keywords
marker
lung cancer
antibodies against
annexin proteins
auto antibodies
Prior art date
Application number
AT06075982T
Other languages
English (en)
Inventor
Samir M Hanash
David Misek
Robert Hinderer
David Beer
Franck Brichory
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE426167T1 publication Critical patent/ATE426167T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06075982T 1999-08-06 2000-08-04 Auto-antikírper gegen annexin-proteine als marker fur lungenkrebs ATE426167T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/370,337 US6645465B2 (en) 1999-08-06 1999-08-06 Annexin proteins and autoantibodies as serum markers for cancer

Publications (1)

Publication Number Publication Date
ATE426167T1 true ATE426167T1 (de) 2009-04-15

Family

ID=23459219

Family Applications (3)

Application Number Title Priority Date Filing Date
AT06075982T ATE426167T1 (de) 1999-08-06 2000-08-04 Auto-antikírper gegen annexin-proteine als marker fur lungenkrebs
AT09151524T ATE529751T1 (de) 1999-08-06 2000-08-04 Annexine als marker für lungenkrebs
AT00952594T ATE326699T1 (de) 1999-08-06 2000-08-04 Annexin-proteine und auto-antikörper als serummarker für lungenkrebs und ösophaguskrebs

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT09151524T ATE529751T1 (de) 1999-08-06 2000-08-04 Annexine als marker für lungenkrebs
AT00952594T ATE326699T1 (de) 1999-08-06 2000-08-04 Annexin-proteine und auto-antikörper als serummarker für lungenkrebs und ösophaguskrebs

Country Status (10)

Country Link
US (5) US6645465B2 (de)
EP (3) EP2051079B1 (de)
JP (1) JP4594575B2 (de)
AT (3) ATE426167T1 (de)
AU (1) AU780772B2 (de)
CA (1) CA2380398C (de)
DE (2) DE60028040T2 (de)
DK (2) DK1200832T3 (de)
ES (2) ES2259609T3 (de)
WO (1) WO2001011372A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810040D0 (en) 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
DE60138111D1 (de) * 2000-07-21 2009-05-07 Chemo Sero Therapeut Res Inst Verfahren zur reinigung eines kalziumionen-bindenden proteins
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
WO2002067857A2 (en) 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7214498B2 (en) * 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
WO2003025568A2 (de) * 2001-09-14 2003-03-27 Reinhard Zeidler Identifizierung von antigenen durch xenogene, allogene oder autologe antikörper-vermittelte präzipitation
CA2462216A1 (en) * 2001-11-09 2003-08-07 Benaroya Research Institute At Virginia Mason Antigen panels and methods of using the same
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
US7700307B2 (en) 2003-03-08 2010-04-20 Auvation Limited Mitochondrial stress-70 protein markers for colorectal cancer
WO2005078124A2 (de) * 2004-02-16 2005-08-25 Proteosys Ag Diagnostische marker für krebs
EP1756572B1 (de) * 2004-05-13 2016-02-24 Centre National De La Recherche Scientifique (Cnrs) Vorrichtung zur bindung eines zielelements an ein köderelement sowie nachweisverfahren damit
US20060024722A1 (en) 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
RU2277242C2 (ru) * 2004-08-23 2006-05-27 Александр Владимирович Балюра Способ диагностики опухолей
JP4521575B2 (ja) * 2005-03-17 2010-08-11 国立大学法人 千葉大学 特発性肺線維症の検出マーカー、検出キット及び検出方法
EP1724585A1 (de) * 2005-05-21 2006-11-22 ProteoSys AG Annexin für Krebsrisikofeststellung
EP1724586A3 (de) * 2005-05-21 2007-07-04 ProteoSys AG Annexin für Krebsrisikomanagement
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
PT1889059E (pt) 2005-05-27 2009-10-01 Oncimmune Ltd Métodos de imunoensaio melhorados
WO2006130525A2 (en) * 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
DE502006006593D1 (de) * 2005-09-26 2010-05-12 Ulrich Loos Verfahren zum nachweis von autoimmunantikörpern gegen den tsh-rezeptor und neue tsh- rezeptorchimären
KR20080073740A (ko) * 2005-11-10 2008-08-11 유니버시티 오브 캔터키 폐암 진단 검사
US9347945B2 (en) * 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP2041569A4 (de) * 2006-07-08 2009-11-18 Univ Kentucky Res Found Assay zur diagnose von lungenkrebs
US8574848B2 (en) * 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods
CA2667012A1 (en) * 2006-10-26 2008-05-02 Abbott Laboratories Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
US7776605B2 (en) * 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
US20080305512A1 (en) * 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
WO2009137832A2 (en) * 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
US9581599B2 (en) 2010-06-28 2017-02-28 The Board Of Regents Of The University Of Texas System Diagnosis of benign and cancerous growths by measuring circulating tumor stem cells and serum AnnexinA2
WO2012048190A1 (en) * 2010-10-08 2012-04-12 Regents Of The University Of Minnesota Annexin ii compositions and methods
KR20150010882A (ko) * 2013-07-19 2015-01-29 삼성전자주식회사 아넥신 Ａ2 결합단백질, ｐ53 단백질 및 ｐ18 단백질을 포함하는 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 조성물
US20160291025A1 (en) * 2013-09-18 2016-10-06 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
ES2928331T3 (es) 2013-11-13 2022-11-17 Univ Minnesota Composiciones de variantes de anexina II y métodos
CN104407151B (zh) * 2014-11-19 2016-06-08 汕头大学医学院 Kindlin-2，Myosin-9和Annexin II三蛋白联合预测食管鳞癌患者预后试剂盒
CN113721021B (zh) * 2021-09-16 2023-07-07 郑州大学 Prkcz自身抗体在食管鳞癌辅助诊断中的应用
CN116539885B (zh) * 2023-07-06 2023-09-29 上海秤信生物科技有限公司 用于乳腺癌早期检测的肿瘤自身抗原/抗体组合及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02496A (ja) * 1987-12-24 1990-01-05 Nippon Shinyaku Co Ltd モノクローナル抗体、製法、及び利用法
DE4012341A1 (de) * 1990-04-18 1991-10-24 Behringwerke Ag Monoklonale antikoerper gegen pp4, verfahren zu ihrer herstellung und ihre verwendung
DE4040306A1 (de) 1990-12-17 1992-06-25 Behringwerke Ag Verfahren zur bestimmung von antikoerpern gegen lipocortine
US5405749A (en) * 1991-12-06 1995-04-11 Polans; Arthur S. Method for identifying and purifying a cancer associated retinopathy autoantigen, and testing patient serum for the autoantibody to the autoantigen
JPH0772149A (ja) * 1993-06-30 1995-03-17 Nippon Shinyaku Co Ltd 肝癌又は肝硬変の診断薬及び診断法
JPH0772147A (ja) * 1993-07-02 1995-03-17 Noboru Kaneko 抗アネキシンｖ抗体並びに該抗体の製法及び利用
EP0651253A1 (de) * 1993-11-02 1995-05-03 Abbott Laboratories Immunoassay zum Nachweis menschlicher Autoantikörper
US5658877A (en) * 1995-05-18 1997-08-19 Wisconsin Alumni Research Foundation Method to treat endotoxin effects by administration of 33 kilodalton phospholipid binding protein
EP0991945B2 (de) 1997-06-26 2008-02-20 The Regents Of The University Of Michigan Methode zur identifizierung von tumorantigenen mit autoantikörpern in serum
US20030064406A1 (en) * 1997-10-08 2003-04-03 Noboru Kaneko Process for analyzing annexin-V in urine, and application thereof
AU762512B2 (en) * 1998-12-28 2003-06-26 Atossa Genetics, Inc. Devices, methods and systems for collecting material from a breast duct
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer

Also Published As

Publication number Publication date
AU780772B2 (en) 2005-04-14
EP1734368A3 (de) 2007-03-07
WO2001011372A9 (en) 2002-04-11
ES2259609T3 (es) 2006-10-16
EP2051079A3 (de) 2009-06-10
US20100330587A1 (en) 2010-12-30
EP1734368B1 (de) 2009-03-18
JP2003535309A (ja) 2003-11-25
EP1734368A2 (de) 2006-12-20
AU6526200A (en) 2001-03-05
JP4594575B2 (ja) 2010-12-08
US20060275845A1 (en) 2006-12-07
US20020168696A1 (en) 2002-11-14
ES2320585T3 (es) 2009-05-25
ATE326699T1 (de) 2006-06-15
EP1200832B1 (de) 2006-05-17
CA2380398C (en) 2017-01-31
DK1734368T3 (da) 2009-06-02
US20070037227A1 (en) 2007-02-15
DE60028040D1 (de) 2006-06-22
WO2001011372A1 (en) 2001-02-15
EP1200832A1 (de) 2002-05-02
DK1200832T3 (da) 2006-09-18
EP2051079A2 (de) 2009-04-22
US6645465B2 (en) 2003-11-11
US7759081B2 (en) 2010-07-20
US7955602B2 (en) 2011-06-07
DE60041839D1 (de) 2009-04-30
DE60028040T2 (de) 2006-11-23
US20040048320A1 (en) 2004-03-11
EP2051079B1 (de) 2011-10-19
CA2380398A1 (en) 2001-02-15
ATE529751T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
DE60041839D1 (de) Auto-Antikörper gegen Annexin-Proteine als Marker für Lungenkrebs
ATE246361T1 (de) Verfahren zur bestimmung von ige
Hill et al. Preserved proteins from extinct Bison latifrons identified by tandem mass spectrometry; hydroxylysine glycosides are a common feature of ancient collagen
DE69636075D1 (de) Verbindungen und verfahren zur diagnose von tuberkulose
PT991421E (pt) Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa
LU91756I2 (fr) Denosumab
ATE397660T1 (de) Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
ATE516492T1 (de) Vorrichtung und verfahren zur multianalytbestimmung
ATE554106T1 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
ATE449963T1 (de) Immunoassays unter verwendung von sers (surface enhanced raman scattering)
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
ATE328280T1 (de) Verfahren und zusammensetzungen zur karzinomdiagnose
DE60325382D1 (de) Verfahren zur diagnose von gebärmutterhalskrebs
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
WO2005019831B1 (en) Methods for reducing complexity of a sample using small epitope antibodies
DE60217351D1 (de) Verfahren zur identifizierung von proben eines säugetiers als auch ein kit zur durchführung des verfahrens
DE602006013333D1 (de) Kit und verfahren zum nachweis von urothelkarzinom
WO2004109286A3 (en) Methods for detecting and treating cancer using podocalyxin and/or endoglycan
ATE421693T1 (de) Proteine in der diabetes-proteomanalyse
ATE208040T1 (de) Immunoassay-reagenzien, testsätze und verfahren
ATE352785T1 (de) Verfahren zum nachweis von hepatitis c antigenen
ATE534907T1 (de) Verfahren für den nachweis von l523s-expression in biologischen proben
DE60311278D1 (de) Immunochromatographiesystem und verfahren zur gleichzeitigen identifikation von aga-und t-tg-antikörpern und verwendung dafür zur diagnose der zöliakiekrankheit
EP1674870A3 (de) Hoch-Durchsatz Prion Tests
CN117054385A (zh) 一种高通量蛋白荧光标记方法

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties